Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Neuralstem said it has granted licenses to non-profit academic medical center Cedars-Sinai Medical Center to use its Central Nervous System (CNS) therapy surgical devices for an undisclosed amount.
Subscribe to our email newsletter
Under the licenses, Cedars-Sinai Medical Center can use Neuralstem’s intellectual property surrounding of spinal cord delivery platform, floating cannula, and method for delivering therapeutic agents.
Cedars-Sinai Medical Center is the second group to gain licenses from Neuralstem for using technologies.
Neuralstem holds the exclusive licenses to the platform and cannula technologies, which have been used in a Phase I ALS trial and recently completed at Emory University, covering the delivery of Neuralstem’s NSI-566 neural stem cells into the spinal cords of patients with amyotrophic lateral sclerosis (ALS or Lou Gehrig’s disease).
Neuralstem recently received FDA’s nod to move into a Phase I trial in chronic spinal cord injury using the platform and cannula technologies.
Neuralstem president and CEO Richard Garr said the firm granting second set of licenses for devices further demonstrates the growing acceptance of intraspinal delivery of therapeutics, once thought impossible, in the treatment of spinal cord conditions and diseases.
"We have shown that it can be done safely in our ALS trial in 15 patients, and 18 procedures, in which three patients successfully returned for second transplants," Garr added.